• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CDC: Respiratory Syncytial Virus Prevalence & Risk Factors among Healthy Term Infants, United States

Commonground

Senior Moderator
Early release October 2024
Abstract

In a population-based birth cohort study of respiratory syncytial virus surveillance in the United States, 897/1,680 (53.4%) children were infected during infancy; 25/897 (2.8%) were hospitalized. Among symptomatic infants, 143/324 (44.1%) had lower respiratory tract infections. These data provide benchmarks to monitor effects of maternal vaccines and extended half-life monoclonal antibodies.

Respiratory syncytial virus (RSV) is a leading cause of illness in infants (1). Previous epidemiologic studies of RSV infection during infancy have focused on symptomatic illness, predominantly lower respiratory tract infections (LRTI) and hospitalizations (2). However, population-based surveillance studies to determine prevalence of and risk factors for RSV infection among healthy infants in the United States are lacking​
-snip-
In conclusion, our data are important estimates of the burden of RSV disease and risk factors for infection in healthy term infants. Our findings provide a benchmark to monitor the effects in the United States of recently available maternal vaccines and extended half-life monoclonal antibodies for severe RSV illness prevention in early life (10).​

https://wwwnc.cdc.gov/eid/article/30/10/24-0609_article
 
Back
Top